pdufa.bio
HomeReadouts › February 2027

February 2027 clinical-trial readouts

Updated ยทnext FDA decision on the calendar
trial-readout estimates for February 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
← January 2027March 2027 →
7 readouts
ABCL · Feb 2027 (est.)
LY3819253: Vasomotor Symptoms Associated With Menopause
Awaiting data
SNDX · Feb 2027 (est.)
Revumenib: Acute Myeloid Leukemias
Awaiting data
MRK · Feb 2027 (est.)
Pembrolizumab: Triple Negative Breast Cancer
KYTX · Feb 2027 (est.)
Standard of Care Treatment: Idiopathic Inflammatory Myopathies
Awaiting dataupdated 4mo ago
MLTX · Feb 2027 (est.)
Sonelokimab: Arthritis, Psoriatic
Awaiting data
OCGN · Feb 2027 (est.)
OCU410ST: Retinitis Pigmentosa
Awaiting dataupdated 4mo ago
AZN · Feb 2027 (est.)
R-Chop: Diffuse Large B-Cell Lymphoma
Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).